Avidity Biosciences (Nasdaq:RNA) - Prezzo delle azioni, notizie e analisi

La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

RNA Panoramica delle azioni

Avidity Biosciences, Inc. è un'azienda biofarmaceutica che si occupa della somministrazione di RNA terapeutici.

RNA analisi fondamentale
Punteggio fiocco di neve
Valutazione	3/6
Crescita futura	2/6
Prestazioni passate	0/6
Salute finanziaria	5/6
Dividendi	0/6

Premi

Negoziato a 63.6% al di sotto della nostra stima del suo valore equo

Si prevede che i ricavi cresceranno 69.89% all'anno

Analisi del rischio

Gli azionisti sono stati sostanzialmente diluiti nell'ultimo anno

Attualmente non redditizio e non si prevede che diventerà redditizio nei prossimi 3 anni

Importanti vendite da parte di insider negli ultimi 3 mesi

Avidity Biosciences, Inc. Concorrenti

Ultragenyx Pharmaceutical

NasdaqGS:RARE

US$5.4b

Immunovant

NasdaqGS:IMVT

US$4.3b

IVERIC bio

NasdaqGS:ISEE

US$5.5b

Denali Therapeutics

NasdaqGS:DNLI

US$4.4b

Storia dei prezzi e prestazioni

Riepilogo dei massimi storici, delle variazioni e dei cali di prezzo di tutti i tempi per Avidity Biosciences
Prezzi storici delle azioni
Prezzo attuale dell'azione	US$41.75
Massimo di 52 settimane	US$48.80
Minimo di 52 settimane	US$4.83
Beta	0.89
1Variazione di 1 mese	-7.18%
Variazione a 3 mesi	8.92%
Variazione di 1 anno	499.86%
3Variazione a 3 anni	75.72%
Variazione a 5 anni	n/a
Variazione dall'IPO	46.49%

Notizie e aggiornamenti recenti

Avidity: Moving RNA Development Landscape Forward Towards Rare Muscle Disorders

Aug 16

Avidity Biosciences, Inc. (NASDAQ:RNA) Released Earnings Last Week And Analysts Lifted Their Price Target To US$66.67

Aug 14

Estimating The Intrinsic Value Of Avidity Biosciences, Inc. (NASDAQ:RNA)

Aug 11

Recent updates

Avidity: Moving RNA Development Landscape Forward Towards Rare Muscle Disorders

Aug 16

Avidity Biosciences, Inc. (NASDAQ:RNA) Released Earnings Last Week And Analysts Lifted Their Price Target To US$66.67

Aug 14

Here's Why We're Not Too Worried About Avidity Biosciences' (NASDAQ:RNA) Cash Burn Situation

Mar 01

Avidity Biosciences: DMD Advancement And 2024 Catalysts Make It A Must-Watch

Feb 29

Is Avidity Biosciences (NASDAQ:RNA) In A Good Position To Deliver On Growth Plans?

Nov 04

Here's Why We're Not Too Worried About Avidity Biosciences' (NASDAQ:RNA) Cash Burn Situation

Apr 08

Here's Why We're Not Too Worried About Avidity Biosciences' (NASDAQ:RNA) Cash Burn Situation

Nov 17

Avidity slips 20% as FDA places lead asset on partial clinical hold

Sep 27

We Think Avidity Biosciences (NASDAQ:RNA) Can Afford To Drive Business Growth

Jul 29

Avidity stock rises amid Chardan starting coverage with Buy

Jul 20

Avidity, Dyn gain as Raymond James turns bullish on targeted oligonucleotides

Jul 12

We're Hopeful That Avidity Biosciences (NASDAQ:RNA) Will Use Its Cash Wisely

Mar 26

Avidity Biosciences: Risks And Potential

Dec 09

We Think Avidity Biosciences (NASDAQ:RNA) Can Afford To Drive Business Growth

Nov 30

Rendimenti per gli azionisti

	RNA	US Biotechs	US Mercato
7D	2.4%	3.5%	3.0%
1Y	499.9%	21.0%	24.6%

Ritorno vs Industria: RNA ha superato il US Biotechs che ha restituito 14.9 % nell'ultimo anno.

Rendimento vs Mercato: RNA ha superato il mercato US che ha restituito 25.4 % nell'ultimo anno.

Volatilità dei prezzi

Is RNA's price volatile compared to industry and market?
RNA volatility
RNA Average Weekly Movement	7.9%
Biotechs Industry Average Movement	10.4%
Market Average Movement	6.4%
10% most volatile stocks in US Market	15.3%
10% least volatile stocks in US Market	3.1%

Prezzo delle azioni stabile: Il prezzo delle azioni di RNA è stato volatile negli ultimi 3 mesi.

Volatilità nel tempo: La volatilità settimanale ( 8% ) di RNA è rimasta stabile nell'ultimo anno.

Informazioni sull'azienda

Fondato	I dipendenti	AMMINISTRATORE DELEGATO	Sito web
2012	253	Sarah Boyce	www.aviditybiosciences.com

Avidity Biosciences, Inc. è una società biofarmaceutica che si occupa della somministrazione di RNA terapeutici. L'azienda sviluppa coniugati anticorpo-oligonucleotide (AOC) per il trattamento di malattie precedentemente non trattabili con terapie a base di RNA. Il candidato principale dell'azienda, AOC 1001, è in fase di sperimentazione clinica di fase 1/2 per il trattamento della distrofia miotonica di tipo 1, una rara malattia muscolare monogenica.

Avidity Biosciences, Inc. Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di Avidity Biosciences con la sua capitalizzazione di mercato?
RNA statistiche fondamentali
Capitalizzazione di mercato	US$4.89b
Guadagni(TTM)	-US$252.45m
Ricavi(TTM)	US$10.60m

461.3x

Rapporto P/S

-19.4x

Rapporto P/E

RNA è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Guadagni e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
RNA Conto economico (TTM)
Ricavi	US$10.60m
Costo del fatturato	US$231.30m
Profitto lordo	-US$220.70m
Altre spese	US$31.75m
Guadagni	-US$252.45m

Ultimi guadagni dichiarati

Jun 30, 2024

Prossima data di guadagno

n/a

Utile per azione (EPS)	-2.16
Margine lordo	-2,082.31%
Margine di profitto netto	-2,381.82%
Rapporto debito/patrimonio netto	0%

Come si è comportato RNA nel lungo periodo?

Vedi performance storica e confronto

RNA Panoramica delle azioni

Premi

Analisi del rischio

Avidity Biosciences, Inc. Concorrenti

NasdaqGS:RARE

US$5.4b

NasdaqGS:IMVT

US$4.3b

NasdaqGS:ISEE

US$5.5b

NasdaqGS:DNLI

US$4.4b

Storia dei prezzi e prestazioni

Notizie e aggiornamenti recenti

Avidity: Moving RNA Development Landscape Forward Towards Rare Muscle Disorders

Avidity Biosciences, Inc. has completed a Follow-on Equity Offering in the amount of $300.12 million.

Avidity Biosciences, Inc. has completed a Follow-on Equity Offering in the amount of $300.12 million.

Avidity Biosciences, Inc. (NASDAQ:RNA) Released Earnings Last Week And Analysts Lifted Their Price Target To US$66.67

Estimating The Intrinsic Value Of Avidity Biosciences, Inc. (NASDAQ:RNA)

Avidity Biosciences, Inc. has filed a Follow-on Equity Offering in the amount of $400 million.

Recent updates

Avidity: Moving RNA Development Landscape Forward Towards Rare Muscle Disorders

Avidity Biosciences, Inc. has completed a Follow-on Equity Offering in the amount of $300.12 million.

Avidity Biosciences, Inc. has completed a Follow-on Equity Offering in the amount of $300.12 million.

Avidity Biosciences, Inc. (NASDAQ:RNA) Released Earnings Last Week And Analysts Lifted Their Price Target To US$66.67

Estimating The Intrinsic Value Of Avidity Biosciences, Inc. (NASDAQ:RNA)

Avidity Biosciences, Inc. has filed a Follow-on Equity Offering in the amount of $400 million.

Avidity Biosciences Announces Positive AOC 1044 Data Demonstrated Significant Increase of 25% in Dystrophin Production and Reduction of Creatine Kinase Levels to Near Normal in People Living with Duchenne Muscular Dystrophin Amenable to Exon 44 Skipping in the Phase 1/2 EXPLORE44 Trial

Avidity Biosciences, Inc. Announces Executive Changes

Avidity Biosciences, Inc. has completed a Follow-on Equity Offering in the amount of $400.9 million.

Avidity Biosciences: Muscular Dystrophy Breakthrough Propels To A 'Buy' Upgrade

Avidity Biosciences, Inc. has filed a Follow-on Equity Offering in the amount of $300 million.

Avidity Biosciences: Strong Buy With Promising RNA Therapeutics Pipeline

Avidity Biosciences, Inc. Appoints Simona Skerjanec as Board of Directors

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Avidity Biosciences, Inc. Receives FDA Breakthrough Therapy Designation for Delpacibart Etedesiran (AOC 1001) for Treatment of Myotonic Dystrophy Type 1

New minor risk - Insider selling

Director recently sold US$542k worth of stock

Avidity Biosciences, Inc. announced that it has received $400.208766 million in funding

Consensus revenue estimates increase by 140%

Avidity Biosciences Announces Positive Aoc 1001 Long-Term Data Showing Reversal of Disease Progression in People Living with Myotonic Dystrophy Type 1 Across Multiple Endpoints; Same Key Endpoints Agreed for Phase 3 Harbor™ Trial

President notifies of intention to sell stock

Here's Why We're Not Too Worried About Avidity Biosciences' (NASDAQ:RNA) Cash Burn Situation

Full year 2023 earnings: EPS and revenues miss analyst expectations

Avidity Biosciences: DMD Advancement And 2024 Catalysts Make It A Must-Watch

Avidity Biosciences Receives FDA Rare Pediatric Disease Designation for AOC 1044 for Treatment of Duchenne Muscular Dystrophy in People with Mutations Amenable to Exon 44 Skipping

Avidity Biosciences, Inc. Plans to Initiate the Global Phase 3 Harbour Trial of AOC 1001 for Adults Living with Myotonic Dystrophy Type 1, in Mid-2024

Avidity Biosciences Reports Positive Data Demonstrating Aoc 1044 Delivers Unprecedented Concentrations of Pmo in Muscle Following A Single Dose in Healthy Volunteers from Phase 1/2 Explore44™ Trial for Duchenne Muscular Dystrophy

Consensus revenue estimates increase by 104%

Avidity Biosciences, Inc. announced that it expects to receive $39.999993 million in funding from Bristol-Myers Squibb Company

Consensus revenue estimates increase by 17%

Price target increased by 10% to US$40.80

Is Avidity Biosciences (NASDAQ:RNA) In A Good Position To Deliver On Growth Plans?

New minor risk - Share price stability

Avidity Biosciences, Inc. Presents New Data Regarding Its Clinical Study of AOC 1001 for Adults with Myotonic Dystrophy Type 1

Price target increased by 10% to US$40.80

Consensus revenue estimates increase by 11%

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Avidity Biosciences, Inc. Provides an Update to the Status of the Partial Clinical Hold Related to Its AOC 1001 Product Candidate

Consensus revenue estimates increase by 11%

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Here's Why We're Not Too Worried About Avidity Biosciences' (NASDAQ:RNA) Cash Burn Situation

Price target decreased by 7.8% to US$40.57

Full year 2022 earnings released: US$3.34 loss per share (vs US$2.85 loss in FY 2021)

Chief Scientific Officer exercised options and sold US$224k worth of stock

Avidity Biosciences, Inc. Receives FDA Orphan Drug Designation for AOC 1020 for the Treatment of Facioscapulohumeral Muscular Dystrophy

President notifies of intention to sell stock

Chief Scientific Officer exercised options and sold US$208k worth of stock

Avidity Biosciences Granted FDA Fast Track Designation for AOC 1020 for the Treatment of Facioscapulohumeral Muscular Dystrophy

Chief Scientific Officer exercised options and sold US$831k worth of stock

Price target increased to US$44.00

Avidity Biosciences, Inc. Announces Positive AOC 1001 Phase 1/2 Marina(Tm) Data Demonstrating First-Ever Successful Targeted Delivery of RNA to Muscle - Revolutionary Advancement for the Field of RNA Therapeutics

Here's Why We're Not Too Worried About Avidity Biosciences' (NASDAQ:RNA) Cash Burn Situation

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Avidity Biosciences, Inc. Announces Planned Explore44 Trial of AOC 1044 in Healthy Volunteers and Participants with Duchenne Muscular Dystrophy

Avidity Biosciences, Inc. Announces Phase 1/2 EXPLORE44 Trial of AOC 1044 for Duchenne Muscular Dystrophy Mutations Amenable to Exon 44 Skipping

Avidity Biosciences Announces the Phase 1/2 Fortitude(Tm) Trial of AOC 1020 in Adults with Facioscapulohumeral Muscular Dystrophy

Avidity Biosciences, Inc. Announces FDA Partial Clinical Hold on New Participant Enrollment in Phase 1/2 MARINA™ Trial

Avidity slips 20% as FDA places lead asset on partial clinical hold

President exercised options and sold US$1.1m worth of stock